To compare clinical efficacy and duration of Hugel-tox® (also known as Botulax®) and Botox® for the treatment of essential blepharospasm.
MethodsA total of 48 patients who were injected with Hugel-tox® (17 females, 7 males) or Botox® (18 females, 6 males) from February 2013 to October 2013 were enrolled in the present study. Changes in eyelid closing force and Scott grade before and after injection were analyzed. Adverse events were also evaluated.
ResultsThere were no significant differences between the Hugel-tox® and Botox® groups in clinical efficacy and duration. Before and after injection, changes in Scott grade (Hugel-tox®: -1.17 ± 0.70, Botox®: -1.21 ± 0.72, p = 0.840), changes in eyelid closing force (Hugel-tox®: -1.38 ± 0.58, Botox®: -1.17 ± 0.56, p = 0.212) and duration (Hugel-tox®: 116.08 ± 22.12 days, Botox®: 126.92 ± 38.94 days, p = 0.242) were shown. No serious adverse events were found in either group.
ConclusionsHugel-tox® showed nearly equal efficacy and duration compared with Botox®.